Matthew Wongchenko

16PUBLICATIONS
87CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Liquid biopsiesPredictive and prognostic markersGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|May 09, 2025
Ligand-activated EGFR/MAPK signaling but not PI3K, are key resistance mechanisms to EGFR-therapy in colorectal cancer.

Xueping Qu, Habib Hamidi, Radia M Johnson

|Apr 14, 2025
Clinical Context Shapes the Relationship between Genomic Alterations and Response to AR Inhibitors and Chemotherapy in Metastatic Prostate Cancer.

Kalpit Shah, Matthew H Secrest, Wei Zhou

|Jul 26, 2024
Ipatasertib plus Paclitaxel for Patients with PIK3CA/AKT1/PTEN-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III Trial.

Rebecca A Dent, Sung-Bae Kim, Mafalda Oliveira

|Jul 11, 2024
Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer.

Christopher J Sweeney, Russell Petry, Chang Xu

|May 17, 2022
Author Correction: Tumour gene expression signature in primary melanoma predicts long-term outcomes.

Manik Garg, Dominique-Laurent Couturier, Jérémie Nsengimana

|Dec 15, 2021
Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer.

Zhen Shi, Julia Wulfkuhle, Malgorzata Nowicka

Pageof 3

Frequent Collaborators

2 joint publications

Dominique-Laurent Couturier

2 joint publications

John Tadross

2 joint publications

Nuno A Fonseca

2 joint publications

Manik Garg